Wall Street Bullish on AbCellera Biologics Inc. (ABCL), Here’s Why

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. Wall Street is bullish on AbCellera Biologics Inc. (NASDAQ:ABCL) since the company released its fiscal second-quarter results for 2025.

The company announced several key clinical announcements, for instance, it started dosing in a Phase 1 trial of ABCL635, aimed at treating moderate-to-severe vasomotor symptoms. Moreover, the company also began a Phase 1 trial for ABCL575 for moderate-to-severe atopic dermatitis. The drug targets the OX40 ligand to regulate inflammation and is engineered for dosing every six months.

In addition, AbCellera Biologics Inc. (NASDAQ:ABCL) also topped analyst expectations with revenue of $17.08 million, which grew 133.29% year-over-year and topped estimates by $10.72 million. Although the company posted a net loss of $0.12 per share, this was ahead of the expectations by $0.04.

Several analysts have reiterated their bullish sentiment since the release. On August 14, Truist Financials reiterated a Buy rating on the stock, with a price target of $10. More recently, on September 11, Brendan Smith from TD Cowen also reiterated a Buy rating on the stock without disclosing any price targets.

AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody medicines for various diseases, including cancer, metabolic, endocrine, and autoimmune disorders.

While we acknowledge the potential of ABCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.